Lafayette, CO – According to filings with the U.S. Securities and Exchange Commission, Front Range Biosciences is raising $40,289,461.00 in new funding. Sources indicate as part of senior management President, Nicholas Hofmeister played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Front Range Biosciences

Front Range Biosciences enables a grower to reduce crop loss due to pathogens, quickly sex a plant, and develop new strains of plants that have the most valuable commercial properties. We increase a grower’s profit, reduce its risk, and give it new products. We have the right team of PhD bioscientists, MIT MBAs, DuPont plant experts, and seasoned biotechnology entrepreneurs. We have the right market, little professional competition, and the right product-market fit. Front Range Biosciences is a vertically integrated biotech company with a strong IP portfolio and licensing strategy.

To learn more about Front Range Biosciences, visit http://www.frontrangebio.com/

Contact:
Nicholas Hofmeister, President
617-320-8743
nhofmeister@frontrangebio.com
https://www.linkedin.com/in/nhofmeister/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved